Food and Drug Administration (FDA) approval in May 2022 for type 2 diabetes, November 2023 for chronic weight management, and December 2024 for obstructive sleep apnea, marking it as the first approved therapy for this indication
Some individuals have faced challenges like initial skin irritation, slow progress, or even unrealistic expectations
The problem was its short half-life natural GLP-1 is rapidly degraded by the enzyme DPP-4, making it unsuitable for therapy in its native form
This is just for reference, as this article focuses specifically on the brand-name drug Victoza compared to Jardiance
In parallel, continued development of effective and implementable therapies will be essential to clarify the clinical value of early CHE detection and intervention
In the ACHIEVE-3 Phase 3 trial, orforglipron was superior to oral semaglutide on both HbA1c reduction (approximately 2.2 vs 1.4 percentage points) and weight loss